Biocon Limited
↗Bengaluru, India
Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company headquartered in Bengaluru with U.S. headquarters in Bridgewater, New Jersey. Founded in 1978 by Kiran Mazumdar-Shaw, Biocon is a publicly listed company (since 2004) that develops affordable biosimilars, generic formulations, and complex APIs. The company is a global leader in biosimilars manufacturing and has commercialized products across diabetes, oncology, immunology, and ophthalmology therapeutic areas. Biocon ranks in the top 15 companies worldwide for biomanufacturing capacity and operates in 120+ countries. The company has integrated its subsidiary Biocon Biologics to create a unified global biopharmaceutical leader.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals & Biotechnology
Sub-Industry:Biosimilars, Generic APIs, Complex Biologics
SIZE & FINANCIALS
Employees:10000+
Revenue:$7.3B (₹7,290.70 Cr on TTM basis, 14% YoY growth)
Founded:1978
Ownership:public
Status:operating
FUNDING
Stage:Public Company
STOCK
Exchange:NSE/BSE
Ticker:BIOCON (NSE: BIOCON.NS, BSE: BIOCON.BO, ID: 532523)
Market Cap:$6.2B (₹51,914 Cr as of Jan 2026)
PIPELINE
Stage:Commercial, Phase 3, Phase 2, Phase 1
Lead Drug Stage:Commercial (multiple approved biosimilars)
Modalities:Biosimilars, Monoclonal Antibodies (mAbs), Insulin (recombinant), Generic APIs, Complex Drug Substances, Recombinant Proteins
Trial Phases:-
FDA Approvals:10
EMA Approvals:8
CORPORATE STRUCTURE
Subsidiaries:Biocon Biologics Limited (fully integrated subsidiary), Syngene International Limited (contract research and manufacturing)
Key Partnerships:Mylan/Viatris - Semglee (insulin glargine-yfgn) co-development and commercialization, Civica, Inc. - Strategic collaboration for insulin Aspart manufacturing and marketing (March 2025), Distribution partnerships for Liraglutide in UK and Netherlands retail markets, Regional partnerships for Tacrolimus commercialization in China
COMPETITION
Position:Leader
Competitors:Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Samsung Bioepis (South Korea), Celltrion Inc. (South Korea), Eli Lilly and Company (insulin biosimilars), Sanofi (insulin biosimilars)
LEADERSHIP
Key Executives:
Kiran Mazumdar-Shaw - Executive Chairperson
Siddharth Mittal - Managing Director and CEO
Shreehas P. Tambe - CEO and Managing Director (Biocon Biologics)
Arun Gupta - Chief Operating Officer (Generics Business)
Manoj Kumar Pananchukunnath - Chief Scientific Officer
Vishal Nayyar - Head of Supply Chain
Scientific Founders:Kiran Mazumdar-Shaw (Founder, 1978)
LINKS
Website:biocon.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biocon Limited. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.